Biotechnology 5 August 2026
SK Biopharmaceuticals XCOPRI's US Sales Rise 45.6% While SK's Next Epilepsy Candidate Faces an Enrolment Hold A profitable American franchise led Donghoon Lee to Biohaven's opakalim. The proposed worldwide licence now sits between antitrust progress and an unresolved partial clinical hold.
KRW 224.4bn US XCOPRI quarterly sales
Biotechnology 28 January 2026
Hanmi Pharmaceutical Hanmi's Obesity Drug Wins Korean Approval After Mexican Distribution Agreement Park and Amtmann agreed a Mexican distribution route while Hanmi's obesity medicine was still awaiting Korean approval. Through 2026, Hanmi advanced its diabetes study and secured home-market authorisation, with Pyeongtaek preparing the product Sanfer would take through local approval.
Mexico Exclusive distribution territory
Biotechnology 9 January 2026
HK inno.N Braintree Files Tegoprazan for US Approval to Treat Heartburn and Oesophageal Damage Alan Cooke and Dal-Won Kwak's partnership reached a US application in January 2026. Schnoll-Sussman, Gyawali and Fass then presented different parts of the clinical programme, from healing damaged tissue to reducing heartburn.
3 Indications sought in the NDA
Biotechnology 26 December 2025
Hanmi Pharmaceutical Hanmi Starts Two Phase 2 Trials to Test HM15275 in Obesity and Diabetes Park, Lee and Choi took Hanmi's triple agonist from a June research roadmap into a longer obesity study and a second programme in diabetes. Weight reduction, body composition and glucose control gave the candidate distinct clinical questions to address.
36 weeks Planned long-term dosing
Biotechnology 22 December 2025
Samsung Biologics Samsung Biologics Takes Over GSK's Rockville Plants, Establishing Its First US Production Base Samsung's first US factory purchase kept more than 500 Rockville staff and continuing GSK production in place. After the March 2026 handover, Rim's team integrated the Maryland site into its manufacturing network and reported a Q3 revenue contribution.
USD 280m Announced acquisition figure
Biotechnology 14 November 2025
ABL Bio Lilly Agrees KRW 22 Billion Share Investment After Licensing ABL Bio's Grabody Sang Hoon Lee wanted to take Grabody into a wider range of diseases. Lilly became a research partner in November 2025 and agreed a share subscription two days later; by December the teams were working on multiple candidates.
KRW 22bn Announced equity investment
Biotechnology 30 September 2025
SK Biopharmaceuticals Ono Secures Japanese Approval for SK's Epilepsy Medicine Cenobamate Cho and Sagara's Japanese partnership led to a three-country seizure study, Ono's application and September 2026 approval. The new option addresses patients whose seizures persist despite existing treatment.
Phase 3 Application evidence stage
Biotechnology 22 September 2025
Lunit Agilent and Lunit Plan AI-Assisted Tissue Tests for Drug Research and Trials After Agilent's colorectal-cancer diagnostic approvals, Nina Green and Brandon Suh paired tissue assays with AI interpretation. Their September 2025 collaboration begins in pharmaceutical research and clinical trials.
Nonexclusive Collaboration scope
Biotechnology 19 September 2025
Alteogen Keytruda Qlex Reaches USD 830 Million in Quarterly Sales With Alteogen's Enzyme A shorter injection gave clinicians another way to deliver pembrolizumab, using Alteogen's enzyme. Following US approval and an April billing-code change, Merck reported Qlex quarterly sales rising to USD 830 million in Q3 2026.
377 Randomised participants in supporting study
Biotechnology 19 September 2025
Celltrion / Celltrion USA Celltrion Starts Lilly Production at Branchburg and Plans to More Than Double Capacity The New Jersey acquisition brought an experienced workforce and continuing Lilly production into Celltrion. After December's closing and February's operating start, the company enlarged its planned expansion in March while preparing its own product transfers.
USD 330m Facility-company acquisition consideration
Biotechnology 17 July 2025
Samsung Bioepis Harrow Launches Samsung Bioepis's Byooviz in the US After Biogen's Exit Bioepis chose a specialist eyecare partner for two US biosimilars. Byooviz reached Harrow's channel in July 2026; Opuviz remained on a separate 2027 timetable.
Two products Agreement portfolio scope
Biotechnology 13 June 2025
Alteogen Daiichi Sankyo Begins Phase 1 Testing of Under-the-Skin Enhertu With Alteogen's Enzyme Soon Jae Park's enzyme technology opened a new formulation project for Daiichi Sankyo's cancer medicine. The partner began its patient study in July 2025 and is investigating which subcutaneous dose can support further development.
Phase 1 Reported clinical stage
Biotechnology 27 May 2025
Samsung Bioepis Hadlima's Global Sales Reach USD 231 Million in Nine Months With US Demand Still Growing Bioepis and Organon completed Hadlima's interchangeable presentation range in May 2025. Autoinjectors and syringes widened the dispensing offer around a medicine whose American sales were already growing.
40 mg / 0.4 mL and 40 mg / 0.8 mL Announced autoinjector presentations
Biotechnology 22 May 2025
Samsung Biologics Samsung Biologics Separates Bioepis to Address Potential Conflicts With Drugmaking Clients John Rim separated contract manufacturing from a potentially competing product business. Kyung-Ah Kim took charge of Epis Holdings, while the two organisations pursued different expansion programmes.
KRW 4,557.0bn FY2025 revenue
Biotechnology 23 April 2025
Samsung Biologics Samsung Biologics' New 180,000-Litre Plant 5 Begins Contributing Revenue John Rim opened Plant 5 in April 2025 as Samsung extended automation across its next manufacturing campus. Customer-process qualification followed, and the company reported increasing revenue contributions in Q3 2026.
180,000 L Additional Plant 5 capacity
Biotechnology 7 April 2025
ABL Bio GSK Pays GBP 38.5 Million Upfront to Use ABL Bio's Brain-Delivery Technology Christopher Austin and Sang Hoon Lee joined GSK's drug-development organisation to ABL's IGF1R shuttle. The April 2025 agreement broadened a delivery business that had already worked with Sanofi on a Parkinson's candidate.
GBP 38.5m Stated immediate upfront payment
Biotechnology 1 April 2025
ABL Bio Tovecimig Improves Tumour Response, but FDA Advises a Trial to Show Survival Benefit The ABL-origin antibody improved response and progression-free survival, but Compass later reported FDA advice to demonstrate a survival benefit before filing. October's publication update did not settle that disagreement.
17.1% vs 5.3% Reported overall response rates
Biotechnology 12 March 2025
Celltrion / Celltrion USA Celltrion Launches Steqeyma at an 85% List-Price Discount and Later Reports 15% US Share Thomas Nusbickel's team brought Steqeyma into Celltrion's US immunology business with both injection and infusion presentations, a lower list price and patient support. Accord's later launch sharpened competition before Celltrion reported 15% US share for August 2026.
85% Announced WAC discount
Biotechnology 10 March 2025
Celltrion Celltrion Launches Omlyclo in the US as an Interchangeable Alternative to Xolair Celltrion's first interchangeable Xolair biosimilar progressed from March 2025 approval to October 2026 US availability. European tenders generated sales before that launch; Japanese medical outreach followed a separate timetable.
First Interchangeable Xolair biosimilar
Biotechnology 4 March 2025
Celltrion Celltrion's Denosumab Biosimilars Gain Final FDA Interchangeability After US Launch Stoboclo and Osenvelt reached US customers after Sandoz's competing launch. Final interchangeability followed later, adding a regulatory advantage to a two-brand bone-disease programme.
60 mg/mL; 120 mg/1.7 mL Reported product presentations
Biotechnology 24 February 2025
Samsung Bioepis Sandoz Launches Pyzchiva in the US and Introduces an Autoinjector in Spain Keren Haruvi brought Bioepis's ustekinumab to American patients, while Christophe Delenta added a European pen. The two launches preceded a wider agreement between the companies in March 2026.
24 February 2025 Reported US availability
Biotechnology 31 January 2025
Celltrion Celltrion Brings Avtozma to US Home Treatment After Its Infusion Launch Approval came before patent-permitted entry, and home-use supply followed the infusion product. Celltrion now reports preferred access across the three largest PBMs.
IV and SC Reported formulation scope
Biotechnology 21 January 2025
Yuhan Yuhan's Lazertinib Wins European Approval in a Chemotherapy-Free Lung-Cancer Regimen European approval brought lazertinib and amivantamab together for a defined first-line lung-cancer population. Survival follow-up and a shorter antibody administration route then developed the treatment beyond January's decision.
EU authorisation Regulatory milestone
Biotechnology 10 January 2025
Samsung Bioepis Teva Launches Epysqli at 30% Below Soliris List Price and Gains Final FDA Interchangeability Bioepis kept development and supply while Teva took the US commercial role. The rare-disease launch combined a lower published price with an obligatory safety programme; a later FDA letter completed the interchangeability step.
7 April 2025 Reported US availability
Biotechnology 23 December 2024
SK bioscience SK Bioscience and Sanofi Start PCV21 Phase 3 Trials With More Than 7,700 Participants Planned Jaeyong Ahn and Thomas Triomphe expanded their pneumococcal-vaccine programme as PCV21 entered paediatric Phase 3. The partners were preparing an Andong factory and testing a candidate designed to broaden disease coverage within childhood vaccination.
EUR 50m Contractual upfront
Biotechnology 12 December 2024
SK bioscience SK Bioscience Completes GBP560 mRNA Vaccine Trial With 161 Participants Versus 402 Planned CEPI and SK used Japanese encephalitis as a prototype for faster outbreak responses. Their vaccine-library partnership took GBP560 into an Australian and New Zealand human study, with affordable supply and public-health access written into the original agreement.
402 adults Planned study population
Biotechnology 27 November 2024
Lunit Lunit Signs Salud Digna Imaging AI Deal With Access to Millions of Deidentified Images Salud Digna's diagnostic-access mission brought it into a Fujifilm-linked evaluation with Lunit in 2018. Six years later, the relationship broadened into direct chest-imaging and mammography software supply, deidentified-image research and joint projects.
230+ clinics Reported counterparty network
Biotechnology 18 November 2024
Lunit Lunit Reports Repeat AstraZeneca Deals to Refine Lung-Cancer Mutation-Prediction AI Kristina Rodnikova and Brandon Suh began with the wait for molecular testing. Their researchers developed a slide-based EGFR prediction model, tested it on external material and continued the relationship through further analysis contracts.
Research / validation Announced development stage
Biotechnology 14 October 2024
Dong-A ST / Dong-A Socio Group Accord Launches Imuldosa Syringes at 92% Below Stelara List Price; Cigna Coverage Follows A Korean-Japanese biosimilar programme reached American patients through Intas and Accord. Chrys Kokino's team paired its syringe launch with patient-designed support, then added Express Scripts and Cigna coverage.
18 August 2025 Observed US syringe launch
Biotechnology 10 October 2024
LigaChem Biosciences Ono Begins Phase 1 Testing of LigaChem's LCB97 Cancer Drug Candidate in Japan Yong-Zu Kim and Seishi Katsumata paired a ready-designed cancer candidate with research into further ADCs. Less than two years later, Ono began the candidate's first human study at Japanese cancer centres.
USD 700m LCB97 potential payment ceiling
Biotechnology 8 October 2024
SK bioscience SK Bioscience Agrees USD 3 Million FinaBio Investment for Conjugate-Vaccine Technology Andrew Lees built FinaBio around affordable conjugate-vaccine production. SK's investment agreement linked that specialist carrier-protein business to a Korean manufacturer already making pneumococcal and typhoid vaccines.
USD 3m Announced investment
No company events match these filters.